Objective: We previously reported that the flavonoid cirsimarin exerts in vitro a strong lipolytic activity on isolated adipocytes. This study was therefore designed to evaluate in vivo the effects of cirsimarin on white adipose tissue (WAT) accretion in mice. Methods: Male CD1 mice were injected daily with either vehicle (intraperitoneal (i.p.)) or cirsimarin (25 or 50 mg kg -1 per day, i.p.) for 18 days. Mice were killed and fat pads weighted. Epididymal fat pads were used for cellularity measurement. Effects of cirsimarin treatment on lipolysis and lipogenesis in WAT were assessed. Results: Mice treated with 25 or 50 mg kg -1 per day cirsimarin showed a decrease in retroperitoneal (À29 and À37% respectively, Po0.005) and epididymal (À25 and À28% respectively, Po0.005) fat pad weights compared with controls. This effect was restricted to intra-abdominal WAT as no difference was noticed for subcutaneous inguinal WAT. The decrease in intra-abdominal WAT accretion was due to a decrease in adipose cell diameter (À5 and À8% for 25 and 50 mg kg -1 per day cirsimarin, respectively) resulting in a 14 and 35% decrease in adipose cell volume while no change was noticed in total adipocyte number. Direct injection of cirsimarin (50 mg kg -1 ) to rats did not trigger lipolysis. In contrast, cirsimarin showed in vivo as well as in vitro a strong antilipogenic activity, which may be the critical aspect of its effects on fat accretion in mice. The inhibitory concentration 50% of cirsimarin on lipogenic activity in isolated adipocytes was found to be 1.28 ± 0.04 mM. Cirsimarin given orally reduced intra-abdominal fat accretion in mice. Conclusion: Cirsimarin exerts potent antilipogenic effect and decreases adipose tissue deposition in mice. Cirsimarin could therefore be a potential candidate for the treatment of obesity.
Introduction
Obesity has become the most common metabolic and nutritional disorder in industrial countries and overweight represents one of the most prevalent risk factor for the development of metabolic disorders such as atherosclerosis, insulin resistance or type 2 diabetes. The recent and spectacular increase in the incidence of obesity urged scientists to elucidate the mechanisms of adipose tissue development and to find natural substances able to antagonize excessive fat deposition. Among the natural substances exerting health benefits, recent studies gave pride of place to flavonoids, a group of polyphenolic compounds, ubiquitously present in plants. Numerous studies have shown that food and beverage containing flavonoids, such as fruits, vegetables, red wine and green tea, can improve health and participate in the prevention of common diseases. Indeed, emerging evidences suggest that flavonoids may have beneficial effects on cardiovascular diseases 1, 2 oxidative stress 3 inflammation 4 and obesity in animals as well as in humans. [5] [6] [7] Many flavonoids stimulate lipid mobilization from adipocytes through the inhibition of phosphodiesterase. 8 In adipose cells, cyclic adenosine 5 0 -monophosphate is a key intracellular second messenger to hormonal signals. Its intracellular concentration results from the equilibrium between its production by adenylate cyclase and its degradation by phosphodiesterase. Adenosine 3 0 ,5 0 -monophosphate cyclic triggers lipid mobilization within adipose cells through the phosphorylation of adenosine 3 0 ,5 0 -monophosphate cyclic-dependent protein kinase A and activation of hormone sensitive lipase. Dephosphorylation of adenosine 3 0 ,5 0 -monophosphate cyclic produces adenosine that binds to adenosine A1-receptor at the plasma membrane. This binding activates the A1-receptor and permanently inhibits adenylyl cyclase activity, which in turn inhibits lipolysis. It is noteworthy that the occupancy by adenosine of o1% of adenosine A1 receptors yield a near maximal decrease of adenosine 3 0 ,5 0 -monophosphate cyclic in adipocytes. 9 In contrast, addition of adenosine deaminase to adipose cell suspension produces a ligand-free state during which lipolysis is maximaly stimulated. 10, 11 Extracts of
Microtea debilis Swartz, a plant originating from South America, are used in traditional medicine in Suriname to treat proteinuria. 12 Previous studies have shown that a flavone glucoside named cirsimarin (Molecular weight: 476.4 Da) was the active compound of Microtea debilis. As anti-proteinuric effects of cirsimarin, are due to its A1 receptor antagonist properties, 12, 13 we have previously
shown that cirsimarin was a potent phosphodiesterase inhibitor and that it exerts a strong lipolytic activity on isolated adipose cells. 14 This study was therefore designed to evaluate the in vivo effects of cirsimarin on white adipose tissue (WAT) accretion in mice. Our results indicate that cirsimarin decreases WAT deposition in mice. In this study, we show that cirsimarin can, in the micromolar range, show strong antilipogenic activity on white adipocytes. These results can make cirsimarin as a potential candidate in the treatment of obesity.
Materials and methods

Reagents
All reagents were from Sigma Aldrich (Saint QuentinFallavier, France). ) was from Perkin-Elmer (Courtaboeuf, France).
Cirsimarin
Cirsimarin used in this study was a kind gift from Dr FE Demarne (Gattefossé SA, Saint Priest, France). Cirsimarin was extracted from wild specimens of Microtea debilis Swartz (Phytolaccaceae) as previously described. 14 1 Hand 13 C-NMR analysis (Brucker DRX-500 spectrometer, Brucker, Wissembourg, France), confirmed the structure. The purity of the powder of cirsimarin was 499%. Cirsimarin was freshly dissolved in sodium hydroxide 0.1 M/ dimethylsulfoxide (DMSO) 95/5 (v/v) before use. A gram scale synthesis of cirsimaritin, the aglycone of cirsimarin (see Supplementary material, Figure S1 ), was performed for this study using the synthetic approach used for the production of the structurally related flavone hispidulin. 15 1 H-and 13 C-NMR analysis confirmed the structure of cirsimaritin.
Animals
All experiments were carried out according to the guidelines laid down by the French Ministère de l'Agriculture and EU Council Directive for the Care and Use of Laboratory Animals (No. 02889). Male Wistar rats (250-300 g, 7-8 weeks) and juvenile male CD1 mice (B12 g, 2-3 weeks) were purchased from Harlan (Gannat, France) and kept at 24±1 1C on a 12:12 h light cycle (light on from 0600 h to 1800 h) with a free access to food (65% carbohydrates, 11% fat, 24% proteins (w/w), AO3, 13.4 kJ g -1 , SAFE, Augy, France) and tap water.
Cirsimarin treatment
Mice were adapted to the animal facilities for 1 week before the beginning of the experiment. After the adaptation period, mice were randomly assigned to receive daily intraperitoneal (i.p.) injection of vehicle (0.l ml NaOH/ DMSO: 95/5, v/v), or cirsimarin (25 or 50 mg kg -1 body weight (BW), injected volume 0.1 ml) for 18 days. One group of 10 mice was killed to assess initial adiposity level (day 0 group thereafter referred to as D 0 ).
BW and food consumption BW was measured on a daily basis. Food and water consumptions were measured on days 0, 5, 9, 12, 15 and 18 day, 0 corresponding to the first day of treatment. Food consumption was measured as the difference between the amount given and that removed from the cage.
Blood sampling and tissue dissection
At the end of treatment (D 18 ), mice were weighted and anesthetized with sodium pentobarbital (60 mg kg -1 i.p., Sanofi Santé Animale, France). Mice were killed between 0800 and 1100 h. Naso-anal length was measured to calculate adiposity index (Lee index) as the cubic root of the body mass divided by the naso-anal length. Blood (B1 ml) was rapidly withdrawn from heart puncture in heparinized syringes. Blood samples were centrifuged (1 min, 8000 g), plasmas were collected, aliquoted and snap frozen in liquid nitrogen. Epididymal (eWAT), retroperitoneal (rWAT), subcutaneous inguinal (scWAT) white adipose tissues and interscapular brown adipose tissue (iBAT) were rapidly dissected out according to defined anatomical landmarks, cleaned and weighted. A portion of epididymal fat pad was immediately used for isolation of adipocytes while the remaining tissues were frozen in liquid nitrogen and stored at À80 1C for further analysis. Heart was removed and washed twice in ice-cold saline (4 1C). Great vessels and fat were trimmed away, heart was blotted dry and weighted. Liver and kidneys were dissected out, blotted dry and weighted. The remaining internal organs were removed and the carcass was weighted. All assays were performed at least in duplicates.
Tissue lipid measurement
The muscle and hepatic lipids were extracted using the procedure developed by Folch. 16 The total lipid content was estimated gravimetrically. The dried lipid residues were dissolved in ethanol containing 0.5% (v/v) triton X100 and 3 mM sodium cholate. The tissue cholesterol and triacylglycerols contents were analyzed with the same enzymatic kit as used in the plasma analysis.
Isolation of adipocytes
Adipocytes were isolated from 15 to 30 mg of epididymal fat pad by a modification of the Rodbell's original procedure. 17 Adipose tissue was weighted, minced and digested in a 2 ml vial containing 1250 ml of Krebs Ringer Bicarbonate (KRB) buffer, 25 mM Hepes, 6 mM glucose, 1% fatty acid-free albumin, pH 7.4 with 1.8 mg ml -1 collagenase (type II, C6885, Sigma Aldrich). The vial was shaken (50 cycles min -1 ) at 37 1C for 60 min. The resulting cell suspension was filtered through a nylon mesh (250 mm) and washed three times with 1.5 ml of KRB buffer containing 1% fatty acid-free bovine serum albumin. Then adipocytes were resuspended in KRB containing 1% fatty acid-free bovine serum albumin.
Adipose tissue cellularity
Cell size and number of adipocytes in epididymal fat pad were determined as described by Briquet-Laugier et al. 18 Briefly, microphotographs of isolated adipocytes were acquired from a light microscope equipped with a CCD camera (Leica, Bron, France) and 800-1000 cell diameters were measured using Axiocam software (Axiocam, Leica, Bron, France). 19, 20 The mean fat cell volume was calculated, then fat cell number was calculated by dividing the tissue lipid content (estimated by lipid extraction using method of Folch) by the mean adipocyte weight (calculated by multiplying the mean adipocyte volume by the triacylglycerol density namely 0.915). i.p., Largactil, Sanofi-Aventis, France). Polyethylene catheters (PE-10) were implanted in the left common carotid artery and in the right common jugular vein. Rats were given an intravenous injection of sodium heparin (5 mg kg -1 ) to prevent blood clotting in the carotid artery catheter. Blood sample (0.2 ml) was drawn before and at various time points (30-180 min) after i.p. injection of cirsimarin (50 mg kg -1 ) or vehicle. A 0.2 ml bolus of isotonic saline was administered after each withdrawal to replace blood volume. Blood samples were centrifuged 1 min at 8000 g and plasma was collected and snap frozen in liquid nitrogen. The measurement of NEFA in plasma was performed using a kit from WAKO (NEFA-C) according to manufacturer's recommendations. Lipolytic activity was estimated as an increase in plasma NEFA concentration.
DNA and protein assays in eWAT
In vitro antilipogenic activity of cirsimarin (rat adipocytes) Male Wistar rats (250-300 g) were killed with CO 2 . Adipocytes were isolated from 2 to 3 g of epididymal fat pad as described above. Lipogenesis was measured in isolated rat adipocytes as the incorporation of At the end of treatment, mice were weighted and killed by cervical dislocation. Naso-anal length was measured to calculate Lee index. Blood (B1 ml) was rapidly withdrawn from heart puncture in heparinized syringes for plasma cirsimaritin measurement. Blood samples were centrifuged (1 min, 8000 g), plasmas were collected and snap frozen in liquid nitrogen. eWAT, retroperitoneal WAT and subcutaneous inguinal WAT were dissected out according to defined anatomical landmarks, cleaned and weighted to the nearest milligram.
Plasma cirsimaritin measurement Plasma concentration of cirsimaritin was measured using high-performance liquid chromatography coupled to an ultraviolet detector (LC 1100 series, Agilent Technologies, Massy, France). Briefly, cirsimaritin was extracted from plasma with ethyl acetate and redissolved in 200 ml of methanol. In all, 30 ml of redissolved sample was injected on a reverse phase column (C18), which was eluted in an isocratic mode with a mobile phase consisting of water/acetic acid/acetonitrile:560/ 40/400 (v/v/v) at 1 ml min -1
. Detection was performed using a diode array detector (Agilent Technologies) at 330 nm. Calibration curves were constructed by dissolving appropriate amount of cirsimaritin in methanol. The recorded highperformance liquid chromatography retention time for cirsimaritin was 10.03 ± 0.1 min.
Statistical analysis
Data are expressed as mean ± s.e.m. All analyses were conducted using StatView 4.5 for Windows (Abacus Concepts, Berkeley, CA, USA). BW, organ weight, food and water intake values were compared using two-way analysis of variance (ANOVA) with one between-subject factor (treatment) and one within-subject factor (time). WAT weights were compared using a three-way ANOVA (treatment, dose and WAT site). When appropriate, individual comparisons were carried out with post hoc Fisher's least significant difference method test. Data regarding tissue weights and plasma parameters were subjected either to one-way ANOVA with one between-subject factor (treatment) or to linear regression analysis (metabolites, hormones and so on). Doseresponse curves for antilipogenic activity of cirsimarin were fitted using open source 'R' software (http://www.r-project. org/) to calculate inhibitory concentration 50% (IC 50 ) value. Differences were considered significant when Po0.05.
Results
Effect of chronic treatment with cirsimarin on body and organ weights To evaluate the in vivo activity of cirsimarin, mice were given for 18 days daily injection of cirsimarin (25 or 50 mg kg -1 per day) or vehicle. Biometric data for each group are shown in Table 1 . BWs of cirsimarin-treated animals were not significantly altered compared with vehicle-treated animals (see Supplementary materials, Figure S2 ). In good agreement, growth parameters were not affected by cirsimarin treatment (daily weight gain, body length, Lee index). 
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Cirsimarin selectively decreases intra-abdominal WAT accretion Cirsimarin treatment significantly reduced accretion of intraabdominal fat pad, that is, retroperitoneal and epididymal fat pads while no effect was noticed on sub-cutaneous fat pad, that is, inguinal fat pad (Figure 1) BW per day cirsimarin-treated mice are shown in Figure 2 . A significant shift leftward was observed in frequency distribution of adipocyte diameters of mice treated with cirsimarin compared with control animals (n ¼ 9-10, Po0.05). The cellular characteristics of epididymal WAT in vehicle-and cirsimarin-treated mice are shown in Table 2 day cirsimarin groups, respectively (n ¼ 8-10, nonsignificant). As DNA amount reflects adipose cell number more accurately than every other method, we also performed a DNA assay in eWAT. The results of fluorometric measurement of DNA content in eWAT of cirsimarin-and vehicle-treated mice are shown in Table 2 . No difference was observed in DNA content excluding a decrease in the total number of adipocytes in eWAT pads. In mouse Purkinje cells, that is, cortical neurons, taken as model of differentiated and unproliferative cells, the amount of DNA was 7.6±0.2 pg per cell. 23 The calculation of the number of adipocytes per fat was performed using the total amount of DNA per pad and a mean DNA amount of 7.6 pg per cell. The total number of adipocytes per epididymal fat pad, calculated from DNA content, were 5.60 ± 0.64, 6.39 ± 0.67 and 6.93 ± 1.03 million for vehicle, 25 and 50 mg kg -1 BW per day cirsimarin groups, respectively (n ¼ 8-10, nonsignificant). These results exactly matched the result obtained with the calculation based on the mean cell weight (using measurement of cell diameters and WAT lipid content) excluding a difference in adipocyte numbers per fat pad between groups.
Metabolic analysis
Blood metabolic parameters (glucose, NEFA, triacylglycerols and cholesterol) and insulin levels were not altered in response to cirsimarin (Table 3) . Cirsimarin did not modify triacylglycerols or cholesterol levels in the liver nor the total lipid content in muscles (Table 3) . Plasma adiponectin concentration showed a slight increase that failed to reach statistical significance in cirsimarin-treated mice (n ¼ 8-10, P ¼ 0.08). In good agreement with the reduction of fat accretion observed in cirsimarin mice, we noticed a significant decrease in plasma leptin concentration (n ¼ 8-10, Po0.05).
Cirsimarin showed antilipogenic rather than antilipolytic activity in vivo We previously showed that cirsimarin showed in vitro lipolytic activity. 14 In an attempt to test the in vivo lipolytic activity of cirsimarin, rats were injected with cirsimarin (50 mg kg -1 i.p.)
or vehicle, and plasma-free fatty acid levels were measured for 180 min as an index of lipolysis (Figure 3a) . I.p. injection of cirsimarin 50 mg kg -1 did not increase plasma-free fatty acid levels excluding a marked in vivo lipolytic effect (n ¼ 5, P ¼ 0.782). A reduced adipocyte volume can result from an increased lipolysis, a reduced lipogenesis or both. To get an insight into the mechanisms of cirsimarin action in mice, lipogenesis was therefore measured in WAT (Figure 3b ). To this end, mice were treated for 15 days with cirsimarin and lipogenesis was measured on isolated adipocytes. Chronic treatment with cirsimarin 25 or 50 mg kg -1 per day decreases adipocyte lipogenesis (À18 and À27%, respectively) compared with vehicle-treated mice (n ¼ 5, Po0.05). As a summary, the decrease in WAT accretion observed in mice after cirsimarin treatment is due to antilipogenic rather than antilipolytic effects of cirsimarin.
Cirsimarin inhibits lipogenesis in isolated rat adipocytes
To calculate the pharmacodynamic parameters, the doseresponse antilipogenic activity of cirsimarin was measured Cirsimarin inhibits adipose tissue accretion B Zarrouki et al in vitro on rat isolated adipocytes. Pre-incubation of adipocytes with cirsimarin (0.1-100 mM) for 1 h induced a dose-dependent decrease in lipogenesis (Figure 4 ). The IC 50 was 1.28 ± 0.04 mM (n ¼ 4). The maximal inhibitory effect (À80%, Po0.05) was observed from a concentration of 10 mM cirsimarin. For these experiments, cirsimarin was dissolved in NaOH 0.1 M/ DMSO:95/5 (v/v) and then serially diluted with the KRB buffer before adding to the reaction mixture. The final concentration of DMSO was therefore carefully kept under 0.1% (v/v) to avoid any interference with the lipogenesis assay. It is noteworthy that under these conditions, vehicle alone did not affect lipogenic rate (data not shown). Cirsimarin (0.1-100 mM for 1 h) did not alter adipocyte viability estimated using Trypan blue exclusion (data not shown).
Oral administration of cirsimarin decreases fat accretion in mice
We tested the effects of 10 days of oral administration of cirsimarin (30 mg kg -1 per day) on fat accretion in mice (Table 4) . The ANOVA indicates a main effect of treatment (Po0.05), a main effect of WAT site (Po0.01), as well as a treatment Â WAT site interaction (Po0.05). Indeed, eWAT and retroperitoneal WAT weights were decreased by 41% (N ¼ 6, Po0.01) and 33% (N ¼ 6, Po0.05), respectively in cirsimarin-treated animals while no difference was noticed for inguinal WAT. Cirsimarin 30 mg kg -1 per day orally significantly reduced fat accretion in mice showing that cirsimarin was active after oral administration. We performed the measurement of plasma cirsimarin after oral administration of 30 mg kg -1 of cirsimarin. After oral administration of cirsimarin, cirsimarin could not be detected in plasma, but the plasma level of cirsimaritin, the aglycone form of cirsimarin, was found to be 0.812±0.083 mM 3 h after oral administration.
Discussion
We previously reported that cirsimarin exerts in vitro a strong lipolitic activity on rats adipocytes. 14 To go further, in this study, cirsimarin was evaluated in vivo for its putative effects on fat accretion in male mice. To this end, male CD1 mice were given daily injection of cirsimarin (25 or 50 mg kg -1 ) for 18 days. At the end of the treatment, adiposity and metabolic properties of WAT were analyzed. Our data clearly show that cirsimarin decreases intra-abdominal adipose tissue accretion and strongly inhibits lipogenesis in white adipocytes.
Energy accumulation, that is, adiposity level, results from the strict difference between energy intake (that is, food intake) and energy expenditure. The fat mass loss effect of cirsimarin may have been due to a reduction in food intake resulting from anorexigenic activity of cirsimarin. However, the present results have shown that cirsimarin lowered adipose tissue weights but food intake remained unaffected. We did not measure locomotor activity in the present work, however, no major behavioral change was noticed using open field test and especially no increase in horizontal locomotor activity (see Supplementary Table 2 ). The effect of cirsimarin was restricted to WAT as no change was noticed in interscapular brown adipose tissue weight. Epididymal adipose tissue was reduced by 10 and 21%, whereas retroperitoneal was decreased by 6 and 28% in response to 25 and 50 mg kg -1 per day of cirsimarin, respectively (Po0.05). In contrast, inguinal adipose tissue mass was not affected by cirsimarin (Figure 1 ), suggesting that it mainly affects intraabdominal adipose depots. Structural and functional differences exist between intra-abdominal and subcutaneous WAT that could account for the differential effect of cirsimarin on intra-abdominal and subcutaneous fat pads. 24 As oral administration of cirsimarin (that is, oral gavage) gave similar results, we can exclude that these discrepancies result Cirsimarin inhibits adipose tissue accretion B Zarrouki et al from a local action of cirsimarin on nearby intra-abdominal fat depots (that is, epidydimal and retroperitoneal). Plasma leptin level is positively correlated with adipose tissue accretion. In good agreement with WAT mass reduction, plasma leptin levels were decreased under cirsimarin treatment (Table 3 , Po0.05), whereas plasma adiponectin levels tended to increase (Table 3 , P ¼ 0.08, nonsignificant). Cellularity analysis of epididymal fat pad indicated that the lower adiposity was due to a hypotrophia (that is, reduction of fat cell size) rather than a hypoplasia (that is, a reduction in the number of adipose cells per fat pad, Table 2 ). Indeed, the frequency distribution of adipose cell diameters in epididymal adipose tissue was significantly shifted to the left, indicating a homogeneous reduction of adipose cell sizes. A reduced adipocyte volume can result from an imbalance between lipolytic and lipogenic activities. To get an insight into the mechanisms of cirsimarin action in mice, we evaluated the metabolic potentialities of WAT after 18 days of treatment with cirsimarin through the measurement of cirsimarin induced lipolysis and de novo lipogenesis. In a previous study, we showed that cirsimarin exerts a strong lipolitic activity on adipocytes isolated from rats with an effective concentration 50% (EC 50 ) of 25 ± 10 mM compared with caffeine (EC 50 ¼ 490 ± 80 mM); The lipolytic activity of cirsimarin resulting from both its antagonist activity on adenosin A1 receptor and its inhibitory effect on phosphodiesterase.
14 As an isoflavone cirsimarin shares some basic structural similarities with genistein, an isoflavone found in high concentrations in soy and soy products. It has been reported that genistein stimulates lipolysis in isolated rat adipocytes 25 and decreases adipose deposition in mice. 26 The in vivo effect of cirsimarin on adipose tissue weight was very similar to that observed in female C57Bl6 mice treated with genistein 80 mg kg -1 per day. 26 We, however, failed to observe any in vivo lipolitic activity of cirsimarin because its administration did not rise plasma NEFA concentration in rat (Figure 3a) . Nevertheless, cirsimarin showed a potent antilipogenic activity in WAT evaluated through the accumulation of [
14 C]-acetate in triacylglycerols. In this study, we showed that cirsimarin exerts a strong and dose-dependent antilipogenic activity on adipocytes isolated from rats with an IC 50 of 1.28 ± 0.04 mM namely 19.5-fold lower value than for its lipolytic effect. Oral administration of cirsimarin significantly reduced fat accretion in mice showing that cirsimarin was active after oral administration. We performed the measurement of plasma cirsimarin after oral administration of 30 mg kg -1 cirsimarin and were unable Figure 4 Antilipogenic activity of cirsimarin on isolated rat adipocytes. Lipogenesis was measured as the incorporation of [
14 C]-acetate into total lipids. Data are expressed as mean ± s.e.m. for n ¼ 4 independent experiments. Different letters indicate significant differences between the means at Po0.05. Insert: cerulenin (10 mM) was used as a positive control. *** indicate Po0.005. [29] [30] [31] The pharmacological inhibition of FAS has been shown to mediate profound fat mass loss in rodents. 32 Many flavonoids (genistein, morin) were reported to efficiently inhibit FAS with IC 50 values ranging from 2 to 112 mM. 33 As cirsimarin shares some characteristics with these flavonoids described to inhibit FAS, it is tempting to speculate that cirsimarin could decrease WAT lipogenesis through a direct inhibition of FAS. Surprisingly, the effect of some FAS inhibitors on BW were mediated through their action on central nervous system rather than their direct action on adipose tissue. Trans-4-carboxy-5-octyl-3-methylenebutyrolactone (C75), a synthetic FAS inhibitor, causes anorexia and profound weight loss in lean mice, 32 diet-induced obese mice, 34, 35 genetically obese (ob/ob) mice 36 as well as chicken. 37 Fatty acid levels, are in central nervous system an index of energy status and modulate feeding behavior. 38 In hypothalamus, C75 and cerulenin, two well-known FAS inhibitors, modulate the levels of energy intermediates, mainly adenosine 5-triphosphate (ATP) levels, thus, affecting the energy sensor adenosine 5 0 -monophosphate-activated protein kinase leading to a decrease in food intake. 35, 39, 40 In this study, the fat mass loss was not mediated through anorexigenic effect because cirsimarin did not alter food intake in mice. Thus, the decrease in fat mass likely resulted from a direct inhibition of FAS by cirsimarin in white adipocyte leading to a reduced storage of triacylglycerols. Estrogen treatments are described to reduce fat accretion and to decrease adipocyte size in male rats 41 or mice. 42 Many flavonoids are described to exert phyto estrogenic activities and to modulate fat accretion through estrogen receptormediated mechanisms. 43, 44 In vitro and in vivo studies have shown that daidzein, genistein and glycitein, as well as their glycosides (daidzin, genistin and glycitin) exert a weak estrogenic effect. 45 The structural similarities with genistein and the numerous effects shared with genistein strongly suggest that cirsimarin effects on WAT could at least be in part mediated through estrogen receptor system. Nevertheless, it has been reported that the difference in estrogenbinding affinity is likely due to the exact position and the number of hydroxyl substituents. Genistein containing three hydroxyl groups has a higher binding affinity to estrogen receptor-than daidzein, which contains only two hydroxyl groups. Formononetin with only one hydroxyl group shows a weak affinity for estrogen receptor-a and -b. 44 As cirsimarin has only one hydroxyl group, only a weak affinity for estrogen receptors should be expected. In summary, our results show that cirsimarin exerts a strong antilipogenic effect on white adipocytes and significantly decreases adipose tissue deposition in mice. These results, in the straight coherence with previous results showing the lipolytic activity of cirsimarin on isolated adipocytes, suggest that it could be an efficient tool in the struggle against excessive adipose tissue deposition and could make cirsimarin a potential candidate in the treatment of obesity.
